Functional exploration of heterotrimeric kinesin-II in IFT and ciliary length control in Chlamydomonas

  1. Shufen Li
  2. Kirsty Y Wan
  3. Wei Chen
  4. Hui Tao
  5. Xin Liang  Is a corresponding author
  6. Junmin Pan  Is a corresponding author
  1. MOE Key Laboratory of Protein Sciences, Tsinghua-Peking Center for Life Sciences, School of Life Sciences, Tsinghua University, China
  2. Laboratory for Marine Biology and Biotechnology, Qingdao National Laboratory for Marine Science and Technology, China
  3. Living Systems Institute, University of Exeter, United Kingdom
5 figures, 1 table and 1 additional file

Figures

Figure 1 with 3 supplements
Requirement of the heterotrimeric organization of CrKinesin-II for IFT (See also Figure 1—figure supplements 13).

(A) Schematic diagram of recombinant CrKinesin-II for expression/purification. (B) Overview of chimeric CrKinesin-II constructs with two identical motor domains. The motor domain of FLA10 was …

Figure 1—figure supplement 1
Purification of recombinant CrKinesin-II and chimeric Crkinesin-II with identical motor domains.

(A) Strategy for expression and purification CrKinesin-II. (B) Coomassie-stained SDS-PAGE of purified FLA10/FLA8 from an MBP column (left) and KAP from a Ni column (right). (C) Elution profiles of …

Figure 1—figure supplement 2
Cells expressing chimeric CrKinesin-II with identical motor domains of FLA10 form normal cilia.

(A) HA-tagged FLA10’ (motor domain of FLA10 with FLA8 carboxyl tail) was transformed into an aflagellate mutant fla8. The transformants were expected to form a chimeric motor with two identical …

Figure 1—figure supplement 3
Self-dimerization of FLA10 and FLA8.

(A–B) Self-dimerization of FLA10 and FLA8 is not affected by the level of protein expression. Cells were transfected with 7.5-fold differences in the amount of plasmid DNA (high and low as …

Figure 2 with 1 supplement
Chimeric CrKinesin-IIs with motor domains of HsKinesin-II function in vitro and in vivo (see also Figure 2—figure supplement 1).

(A) Overview of chimeric CrKinesin-II constructs. The motor domains of FLA10, FLA8 or both in CrKinesin-II were replaced with their counterparts of HsKinesin-II, respectively. (B) In vitro motility …

Figure 2—figure supplement 1
Purification of recombinant HsKinesin-II and chimeric CrKinesin-II with motor domains of HsKinesin-II.

(A–C) Expression and purification of recombinant HsKinesin-II. Strategy of expression and purification (A). Purified kinesin-II was subjected to SDS-PAGE analysis followed by coomassie blue staining …

Chimeric KIF3B’/FLA10 motor leads to significant reduction in IFT injection rate but slight decrease in ciliary length.

(A) Velocities of FLA8-YFP and KIF3B’-YFP. The anterograde velocities of FLA8-YFP and KIF3B’-YFP that were expressed respectively in fla8 cells were assayed using TIRF microscopy. ****p<0.0001; …

Figure 4 with 3 supplements
Mathematical modeling predicts a nonlinear scaling relationship between motor velocity and ciliary length (See also Figure 4—figure supplements 13).

(A) A cartoon schematic of kinesin-II mediated IFT in cilia. (B) Simulated kinetics of ciliary assembly during ciliary regeneration. (C) Kinetics of ciliary assembly. Cells were deflagellated by pH …

Figure 4—source data 1

Representative cells images and numerical data for Figure 4C, and numerical data for Figure 4F.

https://cdn.elifesciences.org/articles/58868/elife-58868-fig4-data1-v2.zip
Figure 4—figure supplement 1
Modeling (case 1): the effect of diffusion constant and the number of motors on ciliary length and the timescale to reach final ciliary length.

(A–B) Contour plots of the steady-state cilium length when N, the total number of motors, is varied with the rate of diffusion (D) at two different motor speeds, when only motors are limiting (case …

Figure 4—figure supplement 2
Modeling (case 2): the effect of diffusion constant and the number of motors on ciliary length and the timescale to reach final ciliary length.

(A–B) Contour plots of the steady-state cilium length when N, the total number of motors, is varied with the rate of diffusion (D) at two different motor speeds, when motors and tubulin are both …

Figure 4—figure supplement 3
Modeling (case 3): the effect of diffusion constant and the number of motors on ciliary length and the timescale to reach final ciliary length.

(A–B) Contour plots of the steady-state cilium length when N, the total number of motors, is varied with the rate of diffusion (D) at two different motor speeds, when only motors are limiting and …

Author response image 1

Tables

Appendix 1—key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional
information
Strain, strain background (C. reinhardtii, mt+) 21grChlamdyomonas Resource CenterCC-1690
Strain, strain background (C. reinhardtii, mt+)fla8Chlamdyomonas Resource CenterCC-829
Strain, strain background (C. reinhardtii, mt+)fla10-2Chlamdyomonas Resource CenterCC-4180
Strain, strain background (C. reinhardtii, mt+)FLA10/FLA10’This studyfla8 transformed with a chimeric FLA10’ with FLA10 motor domain and FLA8 tail domain
Strain, strain background (C. reinhardtii, mt+)FLA10/FLA10’::IFT46-YFPThis studyFLA10/FLA10’ strain expressing IFT46-YFP
Strain, strain background (C. reinhardtii, mt+)ift46::IFT46-YFPThis studyift46 rescue strain expressing IFT46-YFP
Strain, strain background (C. reinhardtii, mt+)wt::IFT46-YFPThis studyWild-type 21gr strain expressing IFT46-YFP
Strain, strain background (C. reinhardtii, mt+)fla8::FLA8-YFPThis studyfla8 rescue strain expressing FLA8-YFP
Strain, strain background (C. reinhardtii, mt+)fla8::FLA8-HAThis studyfla8 rescue strain expressing FLA8-HA
Strain, strain background (C. reinhardtii, mt+)fla8::KIF3B’-YFPThis studyfla8 transformed with a YFP tagged chimeric KIF3B’ having KIF3B motor domain and FLA8 tail domain
Strain, strain background (C. reinhardtii, mt+)fla8::KIF3B’-HAThis studyfla8 transformed with an HA-tagged chimeric KIF3B’ having KIF3B motor domain and FLA8 tail domain
Strain, strain background (C. reinhardtii, mt+)fla8::FLA8-HA/IFT46-YFPThis studyfla8::FLA8-HA strain expressing IFT46-YFP
Strain, strain background (C. reinhardtii, mt+)fla8::KIF3B’-HA/IFT46-YFPThis studyfla8::KIF3B’-HA strain expressing IFT46-YFP
Cell line (H. sapiens)HEK293TATCCATCC CRL-3216
Cell line (S. frugiperda)Sf9Expression SystemsSf9
Transfected construct (S. frugiperda)pOCC8-KAP-EGFP-HisThis studyJunmin Pan’s lab
Transfected construct
(S. frugiperda)
pOCC8-KAP3-EGFP-HisThis studySame as above
Transfected construct (S. frugiperda)pOCC25-FLA8-RFPThis studySame as above
Transfected construct (S. frugiperda)pOCC25-KIF3B-RFPThis studySame as above
Transfected construct (S. frugiperda)pOCC25-KIF3B’-RFPThis studySame as above
Transfected construct (S. frugiperda)pOCC52-FLA10-MBPThis studySame as above
Transfected construct (S. frugiperda)pOCC52-KIF3A-MBPThis studySame as above
Transfected construct (S. frugiperda)pOCC52-KIF3A’-MBPThis studySame as above
Transfected construct (H. sapiens)pCMV-FLA8-EGFPThis studySame as above
Transfected construct (H. sapiens)pCMV-FLA10-EGFPThis studySame as above
Transfected construct (H. sapiens)pCMV-FLA8-MBPThis studySame as above
Transfected construct (H. sapiens)pCMV-FLA10-MBPThis studySame as above
Transfected construct (H. sapiens)pCMV-FLA8This studySame as above
Transfected construct (H. sapiens)pCMV-FLA10This studySame as above
Transfected construct (H. sapiens)pCMV-KAPThis studySame as above
Transfected construct (H. sapiens)pCMV-EGFP
(pEGFP-C3)
AddgenepEGFP-C3
AntibodyAnti-HA (rat)Rocheclone 3F101:1000
AntibodyAnti-MBP (mouse)CMCTAGAT00301:1000
AntibodyAnti-GFP (rabbit)AbmartM20004S1:2000
AntibodyAnti–α-tubulin (mouse)Sigma-AldrichT61991:3000
AntibodyAnti-IC69 (mouse)Sigma-AldrichD61681:20000
AntibodyAnti-IFT140 (rabbit)Zhu et al., 2017a1:2000
AntibodyAnti-IFT144 (rabbit)Zhu et al., 2017a1:2000
AntibodyAnti-IFT46 (rabbit)Lv et al., 20171:2000
AntibodyAnti-IFT38 (rabbit)This study1:3000
AntibodyAnti-IFT57 (rabbit)This study1:2000
AntibodyAnti-IFTD1bLIC (rabbit)Meng and Pan, 20161:1000
AntibodyAnti-FLA8 (rabbit)Liang et al., 20141:3000
AntibodyAnti-FLA10 (rabbit)Cole et al., 19981:3000
AntibodyAnti-KAP (rabbit)Liang et al., 20141:3000
AntibodyAnti-KIF3A (rabbit)Abcamab112591:2000
AntibodyAnti-KIF3B (rabbit)Abcamab892781:500
AntibodyAnti-KIFAP3 (KAP3) (rabbit)Abcamab1335371:5000
AntibodyAnti-Mouse IgG (H and L)-HRP Conjugated (goat)EasyBioBE01021:200
AntibodyAnti-Rabbit IgG (H and L)-HRP Conjugated (goat)EasyBioBE01011:200
AntibodyAnti-Rat IgG (H+L), HRP (goat)EasyBioBE01081:200
AntibodyAlexa Fluor 647–conjugated anti-mouse IgG (goat)Molecular probesA212351:200
AntibodyAlexa Fluor 594–conjugated anti-rabbit IgG (goat)Molecular probesA110371:200
Ahemical compound, drugNi-NTA AgaroseQiagen30210
Chemical compound, drugAmylose ResinNEBE8021
Chemical compound, drugAnti-GFP Magarose BeadsSmart-life sciencesSM03801
Chemical compound, drugMini-Complete (EDTA-free)Roche4693132001
Chemical compound, drugMG-132SelleckS2619
Chemical compound, drugMG-101 (ALLN)SelleckS7386
Chemical compound, drugPoly-lysineSigma-AldrichP8920
Software, algorithmImageJNIH Imagehttps://imagej.nih.gov/
Software, algorithmGraphPad Prism 7GraphPad Softwarehttps://www.graphpad.com/
Software, algorithmAdobe Illustrator and Photoshop CS6Adobehttps://www.adobe.com/Illustrator

Additional files

Download links